Drug intelligence / Profile preview

BSAB-2

Development stage: Preclinical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

BSAB-2 is an investigational bispecific antibody designed to target two immune checkpoints, VISTA (V-domain Ig suppressor of T cell activation) and PD-L1 (Programmed death-ligand 1). By simultaneously blocking these negative immune checkpoints, BSAB-2 aims to enhance tumor inhibitory activity and overcome drug resistance observed with existing mono- and combination immune checkpoint blockade therapies. It has shown enhanced tumor inhibitory activity in preclinical models of pancreatic, endometrial, and breast cancers.

Targets

VISTACD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on BSAB-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSAB-2.

Explore the full profile